A new CRISPR therapy from a Chinese biotech firm is poised to challenge US drugmakers, highlighting the competitive landscape in gene editing technologies. This development may prompt CROs to enhance their bioanalytical and CMC capabilities to support advanced gene therapy projects. As global competition intensifies, regulatory strategies and compliance will be critical for companies seeking to maintain a competitive edge.
Source: Endpoints News ↗